Drug intelligence / Profile preview

SRNDE-02

Development stage: Preclinical
Lead developer: Sirius Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SRNDE-02 is an investigational small interfering RNA (siRNA) therapy being developed by Sirius Therapeutics for the treatment of chronic kidney disease (CKD). The drug is designed to utilize siRNA-mediated gene silencing to target specific, currently undisclosed, molecular drivers of renal disease progression. SRNDE-02 is part of a broader pipeline of RNA-based therapeutics that leverage proprietary delivery technologies for targeted tissue distribution, including delivery to the kidney. It is currently in the preclinical or IND-enabling stage of development.

Beyond the preview

Go deeper on SRNDE-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRNDE-02.

Explore the full profile